Home / Insights / Why Does Alzheimer’s Disease Cause Agitation?
Neuropsychiatry
Why Does Alzheimer’s Disease Cause Agitation?
Agitation in Alzheimer’s disease is not simply “bad behavior.” It can emerge from changes in brain networks, reduced ability to communicate needs, medical problems, environmental stress, pain, sleep disruption, or several of these factors at once.
8 minute read
Agitation is a symptom, not a diagnosis
In Alzheimer’s disease, agitation can look very different from one person to another. It may appear as repeated pacing, verbal outbursts, irritability, resistance to care, repetitive movements, or physical aggression. The important question is not only what the person is doing, but what is driving the behavior.
A sudden change deserves particular attention. Infection, pain, constipation, urinary problems, medication effects, dehydration, sleep deprivation, or delirium can produce or intensify agitation. Assuming every behavioral change is “just the dementia” can miss a treatable medical cause.
Key Fact
A new or rapidly worsening behavior change can be a sign of pain, infection, medication effects, delirium, or another medical problem — not just progression of Alzheimer’s disease.
What changes in the brain?
Alzheimer’s affects networks involved in memory, attention, emotion regulation, judgment, and the ability to interpret the environment. As these systems become less reliable, ordinary situations can become confusing or threatening. A person may not remember why a caregiver is approaching, may misinterpret assistance with bathing as intrusion, or may struggle to communicate pain.
Neuropsychiatric symptoms also reflect changes in neurotransmitter systems and distributed brain circuits rather than one single “agitation center.” That complexity helps explain why the same intervention does not work for everyone.
The environment can become part of the problem
Too much noise, unfamiliar people, rushed care, changes in routine, poor lighting, crowding, or an unfamiliar hospital room can increase distress. Late-day fatigue and disrupted sleep-wake rhythms may also contribute to evening worsening often described as sundowning.
The environment is therefore not background scenery. In dementia care, it can either reduce cognitive load or amplify it.
What This Means
The same outward behavior can have different causes. Effective management starts by asking what changed, when it happens, and what the person may be trying to communicate.
Before medication: look for the trigger
A practical approach begins with pattern recognition. When does the agitation happen? During bathing? At shift change? After a medication dose? When the room is noisy? At a particular time of day? Does the person appear to be in pain or trying to leave because they believe they need to go somewhere familiar?
Non-drug approaches may include reducing noise, maintaining predictable routines, simplifying communication, addressing pain, improving sleep, offering meaningful activity, and redirecting attention rather than arguing about facts the person can no longer process reliably.
| What it may look like | What clinicians/caregivers consider |
|---|---|
| Pain or illness: restlessness, resistance, aggression | Medical assessment; look for infection, injury, constipation, urinary problems |
| Overstimulation: pacing, shouting, distress in busy settings | Reduce noise, crowding, competing conversations |
| Communication difficulty: frustration during care | Use short phrases, one-step instructions, reassurance |
| Sleep disruption: late-day or nighttime agitation | Review routines, sleep environment, medications, daytime activity |
| Medication effects: new confusion or agitation after a change | Medication review and clinical reassessment |
When medication enters the discussion
Medication may be considered when agitation is severe, persistent, dangerous, or continues despite efforts to address medical and environmental contributors. Treatment decisions require balancing potential benefit against risks, especially in older adults with multiple medical conditions.
As of 2026, FDA-approved options for agitation associated with dementia due to Alzheimer’s disease include brexpiprazole (Rexulti), an atypical antipsychotic, and dextromethorphan/bupropion (Auvelity), the first FDA-approved non-antipsychotic treatment for this indication. These treatments are not interchangeable, and neither removes the need to assess underlying triggers.
Why “calmer” is not the only goal
A treatment that simply sedates a person may reduce visible movement without improving distress, function, or quality of life. The clinical goal is not to make a person quiet at any cost. It is to reduce dangerous or distressing agitation while preserving alertness, mobility, interaction, and dignity as much as possible.
That requires repeated reassessment. Symptoms change over time, medical conditions evolve, and a treatment that was reasonable during a crisis may not remain necessary indefinitely.
Important Distinction
The clinical goal is not to make a person quiet at any cost. It is to reduce dangerous or distressing agitation while preserving alertness, mobility, interaction, and dignity.
Frequently asked questions
Is agitation inevitable in Alzheimer’s disease?
No. Many people develop behavioral or psychological symptoms, but the type, timing, and severity vary widely.
Is antipsychotic treatment always the first step?
No. Clinicians generally evaluate medical, environmental, and behavioral contributors first unless immediate safety requires a different approach.
What changed in 2026?
The FDA approved dextromethorphan/bupropion (Auvelity) for agitation associated with dementia due to Alzheimer’s disease, making it the first FDA-approved non-antipsychotic option for this indication.
What families should remember
Agitation is often the visible end point of several interacting problems: brain disease, communication difficulty, unmet needs, medical illness, sleep disruption, and environmental stress. Treating the behavior without investigating the cause can lead to unnecessary medication or missed illness.
The most useful question is often not “How do we stop this behavior?” but “What changed, and what is this behavior telling us?”
Related Insights
What Happens Beyond Memory Loss? Behavioral and Psychiatric Symptoms
A broader guide to neuropsychiatric symptoms in Alzheimer’s. Read more →
How Alzheimer’s Disease Changes the Brain
Why damaged brain networks can alter behavior and emotion. Read more →
How Is Alzheimer’s Disease Diagnosed Today?
Why a careful evaluation looks beyond a single symptom. Read more →
Selected References
National Institute on Aging. Coping With Agitation, Aggression, and Sundowning in Alzheimer’s Disease.
National Institute on Aging. Alzheimer’s Caregiving: Managing Personality and Behavior Changes.
U.S. Food and Drug Administration. FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer’s Disease (brexpiprazole), 2023.
U.S. Food and Drug Administration. FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia (Auvelity), 2026.
National Institute on Aging. Common Medical Problems in Alzheimer’s Disease: Information for Caregivers.
May/2/2026